Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2025-01-27 Director's Dealing
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Ongoing Disclosure Notice 2 pages 271.3KB
Director's Dealing Classification · 100% confidence The document is a disclosure notice under the Financial Markets Conduct Act 2013, detailing a director's acquisition of shares in the company. It includes specifics about the director's relevant interests, transaction details, and certification of the information's accuracy. This type of document reports personal share transactions by company directors or senior managers, which aligns with the definition of Director's Dealing filings. There is no indication that this is a full financial report, earnings release, or other types of filings. The document length and content confirm it is not a brief announcement or a report publication notice but a detailed disclosure of insider transactions.
2025-01-27 English
Medicare LCD Effective Date Extended to 24 April 2025
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 27 January 2025 from Pacific Edge regarding the extension of the effective date of a Medicare Local Coverage Determination (LCD) related to genetic testing in oncology. It provides background on the company and the product but does not contain financial statements, detailed financial results, or regulatory filings. The document is short (2885 characters) and serves as an update to shareholders about a regulatory or policy change affecting the company. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings that require substantive financial or regulatory content. It is an announcement about a policy update impacting the company, best classified as a general Regulatory Filing (RNS) since it does not fit other more specific categories.
2025-01-26 English
Pacific Edge Releases Quarterly Volumes for Q3 FY25
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly volume update for Q3 FY25 from Pacific Edge, providing detailed operational metrics such as test volumes, sales force efficiency, and regional performance. It discusses business challenges, strategic responses, and recent contract successes. The content focuses on business performance and operational data for a specific quarter, which aligns with an Interim / Quarterly Report. The document length is 4216 characters, which is relatively short but contains substantive financial and operational data, not merely an announcement or a brief summary. Therefore, it is not a Report Publication Announcement or Regulatory Filing. It is not a full Annual Report or Earnings Release since it provides detailed quarterly operational data rather than just key highlights. Hence, the best classification is Interim / Quarterly Report (IR). Q3 2025
2025-01-21 English
Pacific Edge Release Quarterly Volumes for Q3 FY25 12 pages 4.5MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed quarterly update from Pacific Edge, focusing on test volumes for Q3 FY25, including detailed analysis of Medicare coverage issues, clinical study updates, and sales force efficiency metrics. It contains substantive financial and operational data for a specific quarter (Q3 25), including test volumes, sales metrics, and strategic challenges related to reimbursement. The presence of detailed quarterly data and analysis indicates this is a comprehensive interim/quarterly report rather than a brief earnings release or an announcement. The document length (15,000 characters) and content depth confirm it is not a short announcement or a report publication notice. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-01-21 English
PEB – Trading resumes at market open
Regulatory Filings Classification · 95% confidence The document is a short memorandum from NZX Limited notifying market participants that trading in Pacific Edge Limited shares will resume. It references a market announcement by the company but does not contain any financial data, report content, or detailed disclosures. The document is brief (609 characters) and serves as a regulatory or market operations notice rather than a financial report or detailed announcement. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. Given its nature as a market notice related to trading resumption, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-01-12 English
Novitas finalizes non-coverage determination
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Pacific Edge regarding a finalized non-coverage determination by Novitas, a Medicare Administrative Contractor, affecting reimbursement for their Cxbladder tests. It discusses regulatory decisions, clinical evidence, company responses, and future plans including legal challenges and business restructuring. The document includes a conference call invitation to discuss the determination. It is not a financial report, earnings release, or annual/interim report. It is a regulatory announcement about a significant Medicare coverage decision impacting the company, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Earnings Release or Legal Proceedings Report (LTR) since it is primarily about a coverage determination and company response rather than a lawsuit or financial results. The document length is substantial and contains detailed information, but it is not a formal report or financial statement. Therefore, the best classification is Regulatory Filings (RNS).
2025-01-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.